Nonalcoholic steatohepatitis (NASH) has similar clinical pathological changes to alcoholic hepatitis. It shows increased incidence and young trend year by year. Polyene phosphatidyl choline (PPC) is widely used in clinic for liver disease treatment. The effect and mechanism of PPC on NASH have not been fully elucidated. Thirty healthy male Wistar rats were randomly equally divided into control, NASH group, and PPC group. NASH model was established by high fat diet. PPC was intraperitoneal injected to NASH rat from the second week at 80 mg/kg·d for three weeks. Body weight, liver weight index, ALT, AST, TG, and TC were tested. TNF-α and IL-1β levels were detected by ELISA. NF-κB mRNA and protein expression in liver tissue were determined by real time PCR and Western blot. SOD activity and ROS content were measured by colorimetry. NASH rat presented significantly elevated body weight and liver weight index, increased ROS content, declined SOD activity, enhanced liver function and inflammatory factors expression, and upregulated NF-κB mRNA and protein levels compared with control (P < 0.05). PPC intervention obviously reduced body weight and liver weight index, declined ROS content, amplified SOD activity, decreased liver function, weakened inflammatory factor TNF-α and IL-1β expression, and downregulated NF-κB mRNA and protein levels compared with NASH group (P < 0.05). PPC can play a treatment effect on NASH through regulating oxidative balance, inhibiting inflammatory factors and NF-κB signaling pathway.

中文翻译：

---

多烯磷脂酰胆碱干预对非酒精性脂肪性肝炎的影响及相关机制。

非酒精性脂肪性肝炎（NASH）的临床病理变化与酒精性肝炎相似。它表明发病率逐年增加并且呈年轻趋势。多烯磷脂酰胆碱（PPC）在临床上广泛用于肝病治疗。PPC对NASH的作用和机制尚未完全阐明。将30只健康的雄性Wistar大鼠随机分为对照组，NASH组和PPC组。NASH模型是通过高脂饮食建立的。从第二周开始以80 mg / kg·d腹腔注射PPC给NASH大鼠，持续三周。测试了体重，肝脏重量指数，ALT，AST，TG和TC。通过ELISA检测TNF-α和IL-1β水平。实时荧光定量PCR和Western blot检测肝组织中NF-κB的mRNA和蛋白表达。通过比色法测量SOD活性和ROS含量。与对照组相比，NASH大鼠的体重和肝重量指数显着升高，ROS含量增加，SOD活性降低，肝功能和炎性因子表达增强，NF-κBmRNA和蛋白水平上调（P <0.05）。与NASH组相比，PPC干预显着降低了体重和肝脏重量指数，降低了ROS含量，增加了SOD活性，降低了肝功能，减弱了炎症因子TNF-α和IL-1β的表达，并下调了NF-κBmRNA和蛋白水平（P <0.05）。PPC可通过调节氧化平衡，抑制炎症因子和NF-κB信号通路对NASH起治疗作用。与对照组相比，NF-κBmRNA和蛋白水平升高（P <0.05）。与NASH组相比，PPC干预显着降低了体重和肝脏重量指数，降低了ROS含量，增加了SOD活性，降低了肝功能，减弱了炎症因子TNF-α和IL-1β的表达，并下调了NF-κBmRNA和蛋白水平（P <0.05）。PPC可通过调节氧化平衡，抑制炎症因子和NF-κB信号通路对NASH起治疗作用。与对照组相比，NF-κBmRNA和蛋白水平升高（P <0.05）。与NASH组相比，PPC干预显着降低了体重和肝脏重量指数，降低了ROS含量，增加了SOD活性，降低了肝功能，减弱了炎症因子TNF-α和IL-1β的表达，并下调了NF-κBmRNA和蛋白水平（P <0.05）。PPC可通过调节氧化平衡，抑制炎症因子和NF-κB信号通路对NASH起治疗作用。与NASH组相比，NF-κBmRNA和蛋白水平下调（P <0.05）。PPC可通过调节氧化平衡，抑制炎症因子和NF-κB信号通路对NASH起治疗作用。与NASH组相比，NF-κBmRNA和蛋白水平下调（P <0.05）。PPC可通过调节氧化平衡，抑制炎症因子和NF-κB信号通路对NASH起治疗作用。